2-[N-(4-Chlorophenyl)4-chlorobenzenesulfonamido]-N-phenylacetamide

Catalog No. :
ACGDLA812
CAS No. :
337922-00-6
Molecular Formula :
C20H16Cl2N2O3S
Molecular Weight :
435.33

IUPAC Name:2-((4-chloro-N-(4-chlorophenyl)phenyl)sulfonamido)-N-phenylacetamide

2-[N-(4-Chlorophenyl)4-chlorobenzenesulfonamido]-N-phenylacetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$323.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-[N-(4-Chlorophenyl)4-chlorobenzenesulfonamido]-N-phenylacetamide
IUPAC Name2-((4-chloro-N-(4-chlorophenyl)phenyl)sulfonamido)-N-phenylacetamide
MDL No.MFCD00793134
Molecular FormulaC20H16Cl2N2O3S
Molecular Weight435.33
SMILESO=C(NC1=CC=CC=C1)CN(C2=CC=C(Cl)C=C2)S(=O)(C3=CC=C(Cl)C=C3)=O
InChI KeyOJFOGCLSKAVWTD-UHFFFAOYSA-N
Synonym2-(4-CHLORO[(4-CHLOROPHENYL)SULFONYL]ANILINO)-N-PHENYLACETAMIDE;2-[N-(4-chlorophenyl)4-chlorobenzenesulfonamido]-N-phenylacetamide;Acetamide, 2-[(4-chlorophenyl)[(4-chlorophenyl)sulfonyl]amino]-N-phenyl-
CAS No.337922-00-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACGDLA812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGDLA812 route product structure diagram
    ACGDLA812337922-00-6
Inquiry

2. ACGDLA812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGDLA812 route product structure diagram
    ACGDLA812337922-00-6
Inquiry

Comments (0)